Stay ahead of the curve. Join our newsletter for first access to new treatments, studies and releases.
By entering you agree to our marketing terms & privacy policy

Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly and Company. Unlike many of the GLP-1 medicines people may already be familiar with, Foundayo is taken by mouth as a tablet rather than given as an injection. It has been developed for weight management alongside changes to diet and physical activity.
Yes. Foundayo (orforglipron) is a GLP-1 receptor agonist. It works by activating GLP-1 receptors in the body. This can help reduce appetite and food intake, supporting weight management alongside appropriate nutrition and physical activity.
Foundayo is made by Eli Lilly and Company, the pharmaceutical company that also developed Mounjaro (tirzepatide). Foundayo and Mounjaro are different medicines and contain different active ingredients.
No. Foundayo is taken orally as a tablet. This is one of the key differences between Foundayo and injectable weight-management medicines such as Mounjaro and Wegovy.
According to Eli Lilly, Foundayo can be taken with or without food and does not require the same planning around food and water associated with some other oral medicines.
The tablets should be swallowed whole rather than broken, crushed or chewed. Always follow the instructions supplied with your medicine and the advice of your healthcare professional.
The instructions supplied with the UK medicine should be followed if a dose is missed. Do not take additional doses to compensate for a missed dose unless specifically instructed to do so by a healthcare professional. If you are unsure what to do, speak to your prescriber or pharmacist.
Clinical trials have studied orforglipron for weight management, with participants experiencing different levels of weight loss depending on factors including dose and individual response. However, trial averages cannot predict how much weight an individual person will lose. Weight-management medicines also form only one part of treatment. Nutrition, movement, metabolic health, hormones, sleep, medical history and other individual factors can all influence a woman’s weight and overall health.
Orforglipron is the active ingredient in Foundayo. It belongs to a group of medicines known as GLP-1 receptor agonists. GLP-1 is a hormone naturally produced by the body and is involved in regulating appetite, feelings of fullness and blood sugar. Orforglipron is particularly notable because it is an oral GLP-1, meaning it can be taken as a tablet.
Foundayo is an oral prescription medicine developed for weight management in eligible adults. Although you may see it described online as a “weight loss pill” or “GLP-1 pill”, it is a prescription medicine rather than a general weight loss supplement. As with any prescription weight-management medicine, whether it is appropriate for an individual should be determined by a qualified healthcare professional.
No. Although Foundayo and Mounjaro are both developed by Eli Lilly, they contain different medicines and work differently. Foundayo contains orforglipron, an oral GLP-1 receptor agonist. Mounjaro contains tirzepatide, an injectable medicine that acts on both GIP and GLP-1 receptors. So Foundayo shouldn’t simply be thought of as “Mounjaro in pill form”.
Foundayo is designed to be taken once a day by mouth.
According to the manufacturer, it can be taken with or without food or water.
As a prescription medicine, Foundayo should always be taken exactly as directed by the healthcare professional responsible for your treatment.
Foundayo uses a gradual dose-escalation approach, beginning at a lower dose before potentially increasing over time. The appropriate dose and any changes to it should be determined by a healthcare professional based on factors including an individual’s response to treatment and tolerability. Never change the dose of a prescription medicine without speaking to your healthcare professional.
As with other weight-management medicines, individual results can vary. How someone responds to treatment can depend on many factors, including their health, treatment dose, lifestyle and individual biology. At SheMed, we believe this is why weight management should never be approached as one-size-fits-all.